NIH Child Health Meeting: Grants and Updates Await Public
Published Date: 6/13/2025
Notice
Summary
The Eunice Kennedy Shriver National Institute of Child Health and Human Development is holding a public meeting on September 9-10, 2025, to discuss important health research and review grant applications. Researchers and organizations applying for funding should pay attention, as some sessions will be private to protect sensitive information. You can join in person or online, making it easier to stay in the loop about new child health projects and funding decisions.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Public meeting with live webcast
The National Advisory Child Health and Human Development Council will hold public sessions on September 9, 2025 (9:30 a.m.–10:30 a.m. and 12:45 p.m.–5:00 p.m.) at the NIH Natcher Building in Bethesda, MD, and you can watch live via the NIH Videocast at https://videocast.nih.gov/.
Closed grant review protects confidential information
A portion of the meeting on September 10, 2025 (9:45 a.m.–12:45 p.m.) will be closed to review and evaluate grant applications so that confidential trade secrets, patentable material, and personal information are protected under 5 U.S.C. 552b(c)(4) and (c)(6).
Limited in-person space and accommodations available
Attendance in person is limited to space available at the Natcher Building, 45 Center Drive, Bethesda, MD, and individuals needing special assistance (for example, sign language interpretation) should notify the listed contact in advance: Rebekah S. Rasooly, Ph.D., Phone: 301-827-2599.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Previous / Next Documents
Previous: 2025-10778, National Institute of General Medical Sciences; Cancellation of Meeting
The National Institute of General Medical Sciences canceled its July 10-11, 2025 meeting to review K99/R00 grant applications because the review work is moving to a different office, the Center for Scientific Review. This change affects researchers waiting on these grant decisions but won’t delay funding or cost extra money. The switch aims to streamline the review process and keep things running smoothly.
Next: 2025-10780, National Institute of General Medical Sciences; Cancellation of Meeting
The National Institute of General Medical Sciences canceled its July 17-18, 2025 meeting about reviewing biomedical research centers. This change happened because the meeting’s responsibility moved to a different office, the Center for Scientific Review. If you were planning to attend or follow this meeting, note the switch—no money or new dates were mentioned.